| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
2-Amino-7-furan-2-yl-7,8-dihydro-6H-quinazolin-5-one manufacturers
- NKY80
-
- $62.00
-
2026-08-20
- CAS:299442-43-6
- Purity: 99.88%
- Supply Ability: 10g
|
| | 2-Amino-7-furan-2-yl-7,8-dihydro-6H-quinazolin-5-one Basic information | | Background |
| Product Name: | 2-Amino-7-furan-2-yl-7,8-dihydro-6H-quinazolin-5-one | | Synonyms: | 2-Amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone;Adenylyl Cyclase Type V Inhibitor, NKY80;2-AMINO-7-(FURANYL)-7,8-DIHYDRO-5(6H)-QUINAZOLINONE;AKOS B003518;SALOR-INT L203769-1EA;VITAS-BB TBB000019;2-amino-7-(2-furyl)-7,8-dihydroquinazolin-5(6H)-one;5(6H)-Quinazolinone, 2-amino-7-(2-furanyl)-7,8-dihydro- | | CAS: | 299442-43-6 | | MF: | C12H11N3O2 | | MW: | 229.23 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | 2-Amino-7-furan-2-yl-7,8-dihydro-6H-quinazolin-5-one Chemical Properties |
| Boiling point | 464.9±47.0 °C(Predicted) | | density | 1.360±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Soluble in DMSO or methanol | | form | powder | | pka | 1.85±0.40(Predicted) | | color | off-white to light brown | | Sensitive | Light Sensitive | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. | | InChI | 1S/C12H11N3O2/c13-12-14-6-8-9(15-12)4-7(5-10(8)16)11-2-1-3-17-11/h1-3,6-7H,4-5H2,(H2,13,14,15) | | InChIKey | SOJUSNIBPPMLCC-UHFFFAOYSA-N | | SMILES | Nc1ncc2C(=O)CC(Cc2n1)c3ccco3 |
| Hazard Codes | Xi,T | | Risk Statements | 25 | | Safety Statements | 45 | | WGK Germany | 3 | | HazardClass | IRRITANT | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | 2-Amino-7-furan-2-yl-7,8-dihydro-6H-quinazolin-5-one Usage And Synthesis |
| Description | NKY-80 (299442-43-6) is a potent and selective adenylyl cyclase inhibitor. Selective for AC5 and over AC3 and AC2 (IC50 = 8.3 μM, 132 μM and 1.7 mM respectively).1,2 More recently shown to indiscriminately inhibit AC6.3 NKY-80 is an extremely useful tool for probing the involvement of adenylyl cyclases in cellular signaling.4 | | Uses | NKY 80 is an inhibitor of adenylyl cyclase (AC) and displays a greater affinity for AC5 over AC3 and AC2. Adenyl cyclase inhibitors can be easily modified by tumor targeting structures. | | General Description | A cell-permeable quinazolinone containing a non-nucleoside compound that acts as a potent, selective inhibitor of adenylyl cyclase (AC) type V isoform (IC50 = 8.3 μM, 132 μM and 1.7 mM for type V, III and II, respectively) in the presence of Gsα GTPγS-Forskolin. Displays ~210-fold greater selectivity for type V over the type II isoform. The inhibition is non-competitive with respect to ATP and Forskolin. Regulates the AC catalytic activity in heart and lung tissues. | | Biochem/physiol Actions | Cell permeable: yes | | storage | Store at +4°C | | Background | NKY-80 is an inhibitor of adenylyl cyclase catalytic activity, an essential enzyme that generates cyclic adenosine 3'5'-monophosphate from ATP. At least six distinct classes of ACs have been identified, with isozymes differing in cell localization, tissue distribution, and signaling pathways. NKY-80 is capable of blocking several different AC isozymes, inhibiting type V more strongly than type II or type III. NKY-80 also potently inhibits AC type VI, with an affinity close to that of AC type V. In a rat model of Parkinson's disease, NKY-80 blocked increases of both [(3)H]-GABA release and cAMP production, indicating that AC V/VI expression is a major determinant of increased GABAergic transmission in rats with L-DOPA induced severe dyskinesia. In a study of immune response in insects, NKY-80 reduced levels of hemocyte mobilization in response to bacterial challenge, indicating a role for AC and cAMP in hemocyte regulation and the immune response. | | References | [1] Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms
[2] SANDRA PIERRE. Capturing adenylyl cyclases as potential drug targets[J]. Nature Reviews. Drug Discovery, 2009, 8 4: 321-335. DOI:10.1038/nrd2827
[3] CAMERON S BRAND. Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds.[J]. Journal of Pharmacology and Experimental Therapeutics, 2013, 347 2: 265-275. DOI:10.1124/jpet.113.208157
[4] M CECILIA ORTIZ-CAPISANO. Adenylyl cyclase isoform v mediates renin release from juxtaglomerular cells.[J]. Hypertension, 2007, 49 3: 618-624. DOI:10.1161/01.hyp.0000255172.84842.d2 |
| | 2-Amino-7-furan-2-yl-7,8-dihydro-6H-quinazolin-5-one Preparation Products And Raw materials |
|